Pharmacological Management of Diabetic Nephropathy.
Angiotensin Receptor Antagonists
/ adverse effects
Angiotensin-Converting Enzyme Inhibitors
/ adverse effects
Animals
Diabetes Mellitus
/ diagnosis
Diabetic Nephropathies
/ diagnosis
Glucagon-Like Peptide-1 Receptor
/ agonists
Humans
Hypoglycemic Agents
/ adverse effects
Hypolipidemic Agents
/ therapeutic use
Incretins
/ therapeutic use
Kidney
/ drug effects
Renin-Angiotensin System
/ drug effects
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Treatment Outcome
Diabetic nephropathy
glucagon-like peptide-1 receptor agonists
pharmacological management
renin-angiotensin system inhibitors
sodium-glucose cotransporter
2 inhibitors.
Journal
Current vascular pharmacology
ISSN: 1875-6212
Titre abrégé: Curr Vasc Pharmacol
Pays: United Arab Emirates
ID NLM: 101157208
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
09
2018
revised:
13
11
2018
accepted:
21
11
2018
pubmed:
10
4
2019
medline:
29
9
2020
entrez:
10
4
2019
Statut:
ppublish
Résumé
Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). The aim of this review is to critically discuss available data on the pharmacological management of DN. A comprehensive review of the literature was performed to identify studies assessing the impact of several drug classes on DN. Several studies have been conducted in order to find a novel and effective treatment of DN. So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors. Their antiproteinuric and antihypertensive effects can not only decelerate the progress of DN but prevent its onset as well. Novel antidiabetic drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide- 1 receptor agonists (GLP-1 RA), are promising agents in the therapy of DN, due to their positive effect on renal and cardiovascular adverse events. From lipid-lowering agents, atorvastatin improves DN up to stage 3 and substantially reduces CVD. RAS inhibitors, SGLT-2i and GLP-1 agonists were found to be beneficial for the treatment of DN. Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN.
Identifiants
pubmed: 30961500
pii: CVP-EPUB-97858
doi: 10.2174/1570161117666190405164749
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
GLP1R protein, human
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Hypolipidemic Agents
0
Incretins
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-147Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.